Verona Pharma plc
VRNA
$63.32
-$2.94-4.44%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -163.94M | -173.42M | -153.72M | -125.45M | -63.42M |
| Total Depreciation and Amortization | 1.09M | 1.06M | 1.01M | 896.00K | 783.00K |
| Total Amortization of Deferred Charges | 1.96M | 1.39M | 872.00K | 198.00K | 198.00K |
| Total Other Non-Cash Items | 89.01M | 54.51M | 38.81M | 54.77M | 18.37M |
| Change in Net Operating Assets | -48.27M | -5.74M | 9.26M | 15.75M | -13.98M |
| Cash from Operations | -120.15M | -122.20M | -103.77M | -53.84M | -58.05M |
| Capital Expenditure | -1.10M | -580.00K | -45.00K | -45.00K | -16.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -1.10M | -580.00K | -45.00K | -45.00K | -16.00K |
| Total Debt Issued | 245.00M | 122.50M | 151.21M | 151.21M | 28.71M |
| Total Debt Repaid | -52.26M | -52.26M | -52.26M | -52.26M | -- |
| Issuance of Common Stock | 107.25M | 102.90M | 4.48M | 864.00K | 988.00K |
| Repurchase of Common Stock | -126.09M | -15.45M | -15.88M | -9.74M | -8.26M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 93.45M | 93.09M | 93.07M | 97.69M | -376.00K |
| Cash from Financing | 267.36M | 250.78M | 180.63M | 187.77M | 21.06M |
| Foreign Exchange rate Adjustments | 427.00K | -11.00K | 1.85M | -11.00K | 472.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.53M | 127.99M | 78.67M | 133.87M | -36.53M |